Developer docs
API playgroundTry for free, no card

Search company profiles

Linea System

Full company profile

uuid0021qg6

Namestring
Linea System
Legal namestring
LINEA System, LLC
Websiteurl
lineasystem.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

LINEA System is a privately held, founder-owned software company headquartered in Parsippany, New Jersey, that builds AI-powered tooling for clinical trial site selection and activation. Its platform combines two products: the Research Site Index (RSI), a continuously refreshed proprietary database of more than 248,000 investigator records spanning 186 countries, 228 specialties, and 43,000+ US institution labels; and AcceleTrial, a workflow execution system that automates feasibility outreach, CDA execution, contract milestone tracking, regulatory document collection, and role-based reporting from protocol-defined site ranking through first patient enrolled. The company serves pharmaceutical sponsors, contract research organizations, and biotech sponsors running trials in rare or novel indications, with an explicit focus on the site start-up phase of clinical operations where enrollment delays are most acute.

The underlying technology combines structured data processing (investigator records, trial parameters, historical performance) with natural language processing of protocol documents and feasibility questionnaires. AI scoring evaluates each candidate site across seven protocol-specific dimensions (population fit, investigator experience, operational readiness, diversity, geographic coverage, enrollment reliability, and protocol compatibility), with a specialized adjacent-indication methodology for rare-disease and novel-modality trials. The platform supports 12 UI languages and produces traceable decision documentation to support sponsor audit and compliance requirements.

LINEA sells exclusively through an enterprise field sales motion targeting VP-level and above clinical operations leadership at top pharma, mid-size biotech, and global pharma companies. The standard engagement is an 8–12 week site identification and activation workflow priced under negotiated multi-year enterprise agreements, with an optional managed-services extension covering regulatory document collection, IRB submission support, and site initiation preparation through first patient screened. Pricing is not publicly disclosed. Founded in 2008 by Kathleen Colatrella and relaunched in 2018 as an AI-native platform, LINEA remains a small, bootstrapped company with a reported headcount of 1–10 and no institutional funding rounds disclosed.

Short descriptiontext

LINEA System builds an AI-powered site selection and activation platform for pharmaceutical sponsors, CROs, and biotechs, combining a 248,000+ investigator database (RSI) with a workflow execution system (AcceleTrial) to accelerate clinical trial start-up.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParsippany, United States
HQ citystring
Parsippany
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial site selection, investigator intelligence platform, site activation workflow, clinical trial feasibility, pharma sponsor analytics
Industry3 codes
PRIMARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
NAICS code1 code
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Clinical Trial Site Selection Software
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1AcceleTrial Platform Subscription
TypeSubscription Recurring
Description

Access to the AcceleTrial site activation workflow platform and Research Site Index is provided to authorized customers under separate written agreements (order form, master services agreement, and applicable product terms). The core engagement covers site identification, CDA execution, feasibility screening, and delivery of a qualified site list. An extended activation track is available as a separate scope for sponsors needing deeper support through first patient screened.

lineasystem.com
2Extended Activation Scope
TypeManaged Services
Description

Extended engagement covering regulatory document collection, IRB submission support, site initiation preparation coordination, and timeline monitoring through first patient screened. Scoped separately from core AcceleTrial engagement.

lineasystem.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1Enterprise SaaS / Managed Services – negotiated per engagement
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Product access governed by separate written agreements; no public pricing page or rate card.

lineasystem.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Research Site Index (RSI)
Description

An AI-scored database of 248,000+ investigator records spanning 186 countries and 228 specialties, providing verified intelligence for clinical trial site selection.

lineasystem.com
+1 more record
Core offering1 text field

LINEA System provides an AI-powered investigator intelligence and site activation platform for pharmaceutical sponsors and CROs. The Research Site Index (RSI) is a continuously refreshed database of 248,000+ investigator records across 186 countries and 228 specialties, scored against protocol-specific criteria. AcceleTrial is the companion workflow execution platform that manages feasibility outreach, CDA execution, regulatory document collection, contract milestones, and reporting from ranked site list delivery through first patient enrolled.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Up to 50% faster trial start-up timeline when beginning with the right sites and protocol-aware activation workflow
+7 more records
Product overview1 text field

LINEA System offers a two-product platform for AI-powered clinical trial site selection and activation. The core offering consists of the Research Site Index (RSI), an investigator intelligence database with 248,000+ AI-scored investigator records across 186 countries and 228 specialties, which feeds directly into AcceleTrial—a governed workflow execution platform that automates feasibility outreach, document controls, contract milestone tracking, and site activation from site ranking through first patient enrolled. RSI serves as the intelligence layer that provides verified, protocol-aware site scoring, while AcceleTrial serves as the execution layer that transforms ranked site lists into governed activation workflows.

Product and service2 records
1Research Site Index (RSI)
CategoryClinical Trial Site Intelligence / Investigator Database
Description

An AI-powered investigator intelligence database of 248,000+ investigator records spanning 186 countries, 228 specialties, and 43,000+ US institution labels. Each investigator is scored against protocol-specific criteria across seven dimensions (population fit, investigator experience, operational readiness, diversity, geographic coverage, enrollment reliability, and protocol compatibility). Monthly data refresh with real-time updates on request, validation-backed source persistence, and 12-language UI for global sponsor and operations teams. Serves pharmaceutical sponsors and CROs as the intelligence layer for clinical trial site selection.

2AcceleTrial
CategoryClinical Trial Site Activation Workflow Platform
Description

A site activation workflow execution platform for pharmaceutical sponsors and CROs. Manages site activation workflow, document controls, SLA logic, reporting, and role-based workspaces across sponsor, CRO, site, regulatory, finance, and audit roles. Capabilities include automated feasibility questionnaires with AI response scoring, contract milestone tracking, geographic network mapping, enrollment forecasting, investigator profile intelligence, and protocol document ingestion that auto-configures the scoring engine. Delivered as the activation layer that turns the RSI's ranked site list into governed execution through first patient enrolled, with engagement timelines of 8–12 weeks to a qualified site list for 20–40 site studies.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Advarra provides site activation, IRB review, and clinical technology services to pharma sponsors and CROs — directly comparable to LINEA's site activation and regulatory workflow focus.

TypeDirect peer
Description

Inato is a direct competitor offering an AI-driven clinical trial site selection and activation platform that matches sponsors with qualified investigator sites globally — closely aligned with LINEA's RSI and AcceleTrial value proposition.

TypeDirect peer
Description

Florence Healthcare provides electronic Investigator Site File (eISF) and site activation workflow software for sponsors, CROs, and sites — directly competing with AcceleTrial's document control and activation lifecycle capabilities.

TypeBroad incumbent
Description

Veeva's Vault CTMS and Vault SiteVault offerings address clinical operations, site management, and document workflows across pharma sponsors — adjacent to LINEA's AcceleTrial execution layer with a much broader enterprise footprint.

TypeEmerging player
Description

Castor offers an EDC and clinical trial platform with site management and ePRO capabilities, increasingly used by sponsors for decentralized and hybrid trial execution — an emerging alternative in the same workflow category.

TypeBroad incumbent
Description

IQVIA is the largest CRO and clinical technology provider, offering site identification, feasibility, and study activation services as part of its broader portfolio — overlapping with LINEA's core offering but bundled with EDC, CTMS, and full-service CRO capabilities.

TypeBroad incumbent
Description

Medidata provides the Rave clinical trial platform used by most large pharma sponsors, including site management, EDC, and trial design tools — overlapping with LINEA's site intelligence and activation workflow layer.

TypeDirect peer
Description

Trial Runners is a site management organization (SMO) that activates and manages trial sites for sponsors — directly comparable to LINEA's site activation workflow focus, and notably founded by LINEA Board Advisor Patrick Healy.

TypeBroad incumbent
Description

WCG offers IRB services, site activation support, and clinical trial enablement technology across the sponsor and CRO ecosystem, with overlapping reach in site feasibility and startup acceleration.

TypeEmerging player
Description

ObvioHealth is a digital CRO that uses technology to run decentralized and hybrid trials, with site identification and patient recruitment workflows that overlap with LINEA's site activation thesis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Linea System

Clinical Trial Site Selection Softwarelineasystem.com

LINEA System builds an AI-powered site selection and activation platform for pharmaceutical sponsors, CROs, and biotechs, combining a 248,000+ investigator database (RSI) with a workflow execution system (AcceleTrial) to accelerate clinical trial start-up.

What Linea System does

LINEA System is a privately held, founder-owned software company headquartered in Parsippany, New Jersey, that builds AI-powered tooling for clinical trial site selection and activation. Its platform combines two products: the Research Site Index (RSI), a continuously refreshed proprietary database of more than 248,000 investigator records spanning 186 countries, 228 specialties, and 43,000+ US institution labels; and AcceleTrial, a workflow execution system that automates feasibility outreach, CDA execution, contract milestone tracking, regulatory document collection, and role-based reporting from protocol-defined site ranking through first patient enrolled. The company serves pharmaceutical sponsors, contract research organizations, and biotech sponsors running trials in rare or novel indications, with an explicit focus on the site start-up phase of clinical operations where enrollment delays are most acute.

The underlying technology combines structured data processing (investigator records, trial parameters, historical performance) with natural language processing of protocol documents and feasibility questionnaires. AI scoring evaluates each candidate site across seven protocol-specific dimensions (population fit, investigator experience, operational readiness, diversity, geographic coverage, enrollment reliability, and protocol compatibility), with a specialized adjacent-indication methodology for rare-disease and novel-modality trials. The platform supports 12 UI languages and produces traceable decision documentation to support sponsor audit and compliance requirements.

LINEA sells exclusively through an enterprise field sales motion targeting VP-level and above clinical operations leadership at top pharma, mid-size biotech, and global pharma companies. The standard engagement is an 8–12 week site identification and activation workflow priced under negotiated multi-year enterprise agreements, with an optional managed-services extension covering regulatory document collection, IRB submission support, and site initiation preparation through first patient screened. Pricing is not publicly disclosed. Founded in 2008 by Kathleen Colatrella and relaunched in 2018 as an AI-native platform, LINEA remains a small, bootstrapped company with a reported headcount of 1–10 and no institutional funding rounds disclosed.

Linea System firmographics

Firmographics
Name
Linea System
Legal name
LINEA System, LLC
Website
https://lineasystem.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
LINEA System builds an AI-powered site selection and activation platform for pharmaceutical sponsors, CROs, and biotechs, combining a 248,000+ investigator database (RSI) with a workflow execution system (AcceleTrial) to accelerate clinical trial start-up.
Ownership category
akta.pro rank

Linea System industry classification

Industry
Product category
Clinical Trial Site Selection Software
NAICS
Other Scientific and Technical Consulting Services (54169)
SIC
Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination

Keywords

  • Clinical trial site selection
  • Investigator intelligence platform
  • Site activation workflow
  • Clinical trial feasibility
  • Pharma sponsor analytics

Where Linea System is headquartered

Location

Headquarters

HQ city
Parsippany
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Linea System business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. AcceleTrial Platform Subscription: Access to the AcceleTrial site activation workflow platform and Research Site Index is provided to authorized customers under separate written agreements (order form, master services agreement, and applicable product terms). The core engagement covers site identification, CDA execution, feasibility screening, and delivery of a qualified site list. An extended activation track is available as a separate scope for sponsors needing deeper support through first patient screened.
  2. Extended Activation Scope: Extended engagement covering regulatory document collection, IRB submission support, site initiation preparation coordination, and timeline monitoring through first patient screened. Scoped separately from core AcceleTrial engagement.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise SaaS / Managed Services – negotiated per engagement

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Linea System product offering

Product offering

Core offering

LINEA System provides an AI-powered investigator intelligence and site activation platform for pharmaceutical sponsors and CROs. The Research Site Index (RSI) is a continuously refreshed database of 248,000+ investigator records across 186 countries and 228 specialties, scored against protocol-specific criteria. AcceleTrial is the companion workflow execution platform that manages feasibility outreach, CDA execution, regulatory document collection, contract milestones, and reporting from ranked site list delivery through first patient enrolled.

Product overview

LINEA System offers a two-product platform for AI-powered clinical trial site selection and activation. The core offering consists of the Research Site Index (RSI), an investigator intelligence database with 248,000+ AI-scored investigator records across 186 countries and 228 specialties, which feeds directly into AcceleTrial—a governed workflow execution platform that automates feasibility outreach, document controls, contract milestone tracking, and site activation from site ranking through first patient enrolled. RSI serves as the intelligence layer that provides verified, protocol-aware site scoring, while AcceleTrial serves as the execution layer that transforms ranked site lists into governed activation workflows.

Differentiator

Problem solved

Functional benefit

Brands

  • Research Site Index (RSI): An AI-scored database of 248,000+ investigator records spanning 186 countries and 228 specialties, providing verified intelligence for clinical trial site selection.
  • AcceleTrial

Products and services

  • Research Site Index (RSI) An AI-powered investigator intelligence database of 248,000+ investigator records spanning 186 countries, 228 specialties, and 43,000+ US institution labels. Each investigator is scored against protocol-specific criteria across seven dimensions (population fit, investigator experience, operational readiness, diversity, geographic coverage, enrollment reliability, and protocol compatibility). Monthly data refresh with real-time updates on request, validation-backed source persistence, and 12-language UI for global sponsor and operations teams. Serves pharmaceutical sponsors and CROs as the intelligence layer for clinical trial site selection.
  • AcceleTrial A site activation workflow execution platform for pharmaceutical sponsors and CROs. Manages site activation workflow, document controls, SLA logic, reporting, and role-based workspaces across sponsor, CRO, site, regulatory, finance, and audit roles. Capabilities include automated feasibility questionnaires with AI response scoring, contract milestone tracking, geographic network mapping, enrollment forecasting, investigator profile intelligence, and protocol document ingestion that auto-configures the scoring engine. Delivered as the activation layer that turns the RSI's ranked site list into governed execution through first patient enrolled, with engagement timelines of 8–12 weeks to a qualified site list for 20–40 site studies.

Quantifiable outcome

  • Up to 50% faster trial start-up timeline when beginning with the right sites and protocol-aware activation workflow
  • +7 more outcomes

Companies that use Linea System

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Linea System technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature10 records

Linea System partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Linea System competitors and assessment

Company assessment

Direct peers

  • Advarra: Advarra provides site activation, IRB review, and clinical technology services to pharma sponsors and CROs — directly comparable to LINEA's site activation and regulatory workflow focus.
  • Inato: Inato is a direct competitor offering an AI-driven clinical trial site selection and activation platform that matches sponsors with qualified investigator sites globally — closely aligned with LINEA's RSI and AcceleTrial value proposition.
  • Florence Healthcare: Florence Healthcare provides electronic Investigator Site File (eISF) and site activation workflow software for sponsors, CROs, and sites — directly competing with AcceleTrial's document control and activation lifecycle capabilities.
  • Trial Runners: Trial Runners is a site management organization (SMO) that activates and manages trial sites for sponsors — directly comparable to LINEA's site activation workflow focus, and notably founded by LINEA Board Advisor Patrick Healy.

Broad incumbents

  • Veeva Systems: Veeva's Vault CTMS and Vault SiteVault offerings address clinical operations, site management, and document workflows across pharma sponsors — adjacent to LINEA's AcceleTrial execution layer with a much broader enterprise footprint.
  • IQVIA: IQVIA is the largest CRO and clinical technology provider, offering site identification, feasibility, and study activation services as part of its broader portfolio — overlapping with LINEA's core offering but bundled with EDC, CTMS, and full-service CRO capabilities.
  • Medidata (Dassault Systèmes): Medidata provides the Rave clinical trial platform used by most large pharma sponsors, including site management, EDC, and trial design tools — overlapping with LINEA's site intelligence and activation workflow layer.
  • WCG (WIRB-Copernicus Group): WCG offers IRB services, site activation support, and clinical trial enablement technology across the sponsor and CRO ecosystem, with overlapping reach in site feasibility and startup acceleration.

Emerging players

  • Castor: Castor offers an EDC and clinical trial platform with site management and ePRO capabilities, increasingly used by sponsors for decentralized and hybrid trial execution — an emerging alternative in the same workflow category.
  • ObvioHealth: ObvioHealth is a digital CRO that uses technology to run decentralized and hybrid trials, with site identification and patient recruitment workflows that overlap with LINEA's site activation thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Linea System compliance and trust

Trust signal

Compliance3 records

Linea System financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Linea System leadership team

Management profile

Number of profiles

Profiles5 records

Linea System funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Linea System M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Linea System

What does Linea System do?

LINEA System provides an AI-powered investigator intelligence and site activation platform for pharmaceutical sponsors and CROs. The Research Site Index (RSI) is a continuously refreshed database of 248,000+ investigator records across 186 countries and 228 specialties, scored against protocol-specific criteria. AcceleTrial is the companion workflow execution platform that manages feasibility outreach, CDA execution, regulatory document collection, contract milestones, and reporting from ranked site list delivery through first patient enrolled.

Is Linea System a public or private company?

Linea System is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Linea System founded?

Linea System was founded in 2008. It employs 11 to 50 people.

Where is Linea System based?

Linea System is headquartered in Parsippany, United States, in the North America region.

How does Linea System make money?

Two revenue lines are on record. AcceleTrial Platform Subscription is the primary driver. The others are extended Activation Scope.

Who are Linea System's main competitors?

Direct peers on record are Advarra, Inato, Florence Healthcare and Trial Runners. Broad incumbents are Veeva Systems, IQVIA, Medidata (Dassault Systèmes) and WCG (WIRB-Copernicus Group). Emerging players are Castor and ObvioHealth.

Does Linea System have an API?

No public API is recorded for Linea System.

What industry is Linea System in?

Linea System's product category is Clinical Trial Site Selection Software. Its primary akta.pro industry code is HLAGAAAI, Patient Recruitment, Site Feasibility & Trial Enablement CROs, with a secondary code of HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation). Its NAICS code is 54169 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales